Targeting EGFR/PI3K/AKT/mTOR and Bax/Bcl-2/caspase3 pathways with ivermectin mediates its anticancer effects in a murine model of lung cancer (2025)

Peer-Reviewed Study · Malak MN; Arafa EA; Abdel-Fattah MM; Khalaf MM · August 2025

Malak MN et al., 2025-08: Mouse lung cancer model (urethane-induced NSCLC) in which daily oral ivermectin at 5 mg/kg reduced tumour burden and modulated EGFR/PI3K/AKT/mTOR and Bax/Bcl-2/caspase-3 signalling.

Mice were divided into four groups; (1) normal; (2) oral ivermectin alone (5 mg/kg) daily; (3) NSCLC was induced by urethane (1.5 g/kg, i.p.) at days one and sixty; (4) NSCLC group treated with ivermectin.

n/a (PubMed abstract)

Malak MN et al., 2025-08: Mouse lung cancer model (urethane-induced NSCLC) in which daily oral ivermectin at 5 mg/kg reduced tumour burden and modulated EGFR/PI3K/AKT/mTOR and Bax/Bcl-2/caspase-3 signalling. Study type: urethane-induced NSCLC in mice (4 groups). N: group sizes not stated in the abstract. Country: Egypt (Beni-Suef University). Dose: 5 mg/kg orally daily; comparator: normal mice and untreated NSCLC mice. Declared COI: 'The authors declare no conflict of interest.' This is one of the few genuinely in vivo lung cancer studies for ivermectin. Study type: animal.